Xeltis is a European medical device company based in Zurich, Switzerland and in Eindhoven, The Netherlands. Xeltis is dedicated to transforming standards of care in heart valve replacement and vascular surgery. The company develops implantable products intended to enable the spontaneous growth of natural, healthy heart valves and vessels.
Xeltis‘ proprietary technology, based on Nobel prize-winning science, holds the promise to enable Endogenous Tissue Growth (ETG) for the first time. ETG is a completely new therapeutic category in which surgeons use synthetic biodegradable implants designed to allow the body to repair itself. ETG has the potential to overcome the limitations of current standards of care.